ADHD medications may lower suicide risk in children with hyperactivity, oppositional defiance, and other behavioural disorders, according to new research from the Lifespan Brain Institute (LiBI) of Children’s Hospital of Philadelphia (CHOP) and the University of Pennsylvania. The findings, published today in JAMA Network Open, address a significant knowledge gap in childhood suicide risk and could inform suicide prevention strategies at a time when suicide among children is on the rise.
‘This study is an important step in the much-needed effort of childhood suicide prevention, as it leverages data collected from approximately 12,000 US children to identify an actionable target to reduce childhood suicides,’ said senior author Ran Barzilay, MD, PhD, an assistant professor at LiBI. ‘Early diagnosis and treatment of behavioural symptoms with ADHD medication, particularly among children with severe externalising symptoms, may serve not only to improve learning and behaviour problems, but also to decrease suicidality risk.’
Suicide rates among children have been steadily rising. According to the CDC, suicide was the second leading cause of death among individuals between the ages of 10 and 24 in 2018. Yet the rates are still relatively low in preadolescent children, making it difficult to identify factors that may lead to or prevent suicidal tendencies in this age range. Additionally, there are ethical limitations in enrolling potentially suicidal youth in placebo-controlled randomised clinical trials.
‘In an ideal world, we want to test a medication effect on suicidality with a randomized prospective trial,’ Barzilay said. ‘But given the challenges of conducting such studies, we are obligated as a society and as scientists to generate clinical insights using data collected in large-scale observational studies of children.’
The LiBI researchers, in concert with Gal Shoval, MD of Tel Aviv University, circumvented this barrier by leveraging data from the Adolescent Brain Cognitive Development (ABCD) Study. As the largest long-term study of brain development and health in the country, the ABCD Study sample includes a cohort of 11,878 children between the ages of 9 and 10 who were recruited through school systems. The cohort spans 21 sites across the United States, encompassing more than 20% of the US population in this age group, and includes comprehensive data on child development, including data on mental, social, and emotional health. The magnitude and breadth of data collected in the ABCD study allowed the research team to control for multiple confounders and to dissect specifically the association of ADHD medications with suicidal tendencies.
Performing a secondary analysis of the ABCD Study data, the LiBI researchers found that of the 11,878 children in the study, 8.5% were treated with ADHD medication, such as methylphenidate, Adderall or clonidine, and 8.8% reported past or current suicidality. The researchers found that children expressing suicidal tendencies had more externalizing symptoms and were more likely to receive ADHD medication than non-suicidal children. However, among children who demonstrated significant externalising behaviours, those taking ADHD medications had lesser odds for suicidality, suggesting a moderating role for ADHD medications in these children.
To study whether this effect endured, the researchers analysed data from participants’ one-year follow-up assessments. They found that children with high externalizing symptoms who were treated with ADHD medications at baseline were less likely to be suicidal one year later. Children who were not receiving ADHD medications at baseline but had high externalising symptoms were more likely to be suicidal at the one-year follow up.
‘Given the connection between childhood suicidality and poor adult mental health, these findings emphasise the importance of better and more thorough screening of school-aged children for externalising behavioural symptoms,’ Barzilay said. ‘These symptoms are treatable, and addressing them early has the strong potential to prevent and mitigate serious mental health issues later in life.’
Psychreg is mainly for information purposes only; materials on this website are not intended to be a substitute for professional advice. Don’t disregard professional advice or delay in seeking treatment because of what you have read on this website. Read our full disclaimer.